Ukr.Biochem.J. 2016; Volume 88, Issue 2, Mar-Apr, pp. 56-65


Level of overall hemostasis potential in donor and patient plasma in pathology

L. V. Pyrogova, T. M. Chernyshenko, I. N. Kolesnikova, T. N. Platonova,
G. K. Bereznitsky, Y. M. Makogonenko, E. V. Lugovskoy

Palladin Institute of Biochemistry, National Academy of Sciences of Ukraine, Kyiv;

Coagulation potential (CP), overall hemostasis potential (OHP) and fibrinolysis potential (FP) in plasma of donors and patients with myocardial infarction (MI), stroke (St) and hip joint diseases (HJD) have been investigated using M. Blomback’s global hemostasis assay. Plasma samples of the patients were analyzed with APTT reagent in the presence or absence of t-PA. It was found that the ratio of values of СP, OHP and FP in plasma of patients to those of donors plasma were 78, 60 and 123% at MI; 157, 155 and 162% at St; 128, 131 and 124% at HJD. CP to FP ratio that indicated balance between coagulation and fibrinolytic systems activities were 4.13, 2.5, 4.0 and 4.26 in plasma of donors and MI, St and HJD patients, respectively. These results are evidence of increased fibrinolytic activity in plasma of MI patients. Lag-periods of plasma clotting of MI, St and HJD patients were prolonged by 2.3, 7.2 and 1.5-fold, respectively. Pearson’s correlation analysis between parameters, obtained in vitro studies using global hemostasis assay, and concentrations of the molecular markers (soluble fibrin and D-dimer), which formed in vivo in plasma of MI, St and HJD patients, did not reveal any relationship between them.

Keywords: , ,


  1. Antovic JP, Antovic A. Does recombinant factor VIIa, apart from overall hemostasis, regulate TAFI dependent fibrinolysis? In vitro analysis using overall hemostasis potential (OHP) assay. Thromb Haemost. 2003 Oct;90(4):620-7. PubMed, CrossRef
  2. Antovic JP, Antovic A, He S, Tengborn L, Blombäck M. Overall haemostatic potential can be used for estimation of thrombin-activatable fibrinolysis inhibitor-dependent fibrinolysis in vivo and for possible follow-up of recombinant factor VIIa treatment in patients with inhibitors to factor VIII. Haemophilia. 2002 Nov;8(6):781-6. PubMed, CrossRef
  3. Antovic JP, Antovic A, Sten-Linder M, Wramsby M, Blombäck M. Overall hemostatic potential (OHP) assay-a possible tool for determination of prothrombotic pattern in FXII deficiency. J Thromb Haemost. 2004 Nov;2(11):2058-60. PubMed, CrossRef
  4. Antovic A, Blombäck M, Bremme K, Van Rooijen M, He S. Increased hemostasis potential persists in women with previous thromboembolism with or without APC resistance. J Thromb Haemost. 2003 Dec;1(12):2531-5. PubMed, CrossRef
  5. He S, Wallèn H, Bark N, Blombäck M. In vitro studies using a global hemostasis assay to examine the anticoagulation effects in plasma by the direct thrombin inhibitors: dabigatran and argatroban. J Thromb Thrombolysis. 2013 Feb;35(2):131-9. PubMed, CrossRef
  6. He S, Antovic A, Blombäck M. A simple and rapid laboratory method for determination of haemostasis potential in plasma. II. Modifications for use in routine laboratories and research work. Thromb Res. 2001 Sep 1;103(5):355-61. PubMedCrossRef
  7. Antovic A, Blombäck M, Bremme K, He S. The assay of overall haemostasis potential used to monitor the low molecular mass (weight) heparin, dalteparin, treatment in pregnant women with previous thromboembolism. Blood Coagul Fibrinolysis. 2002 Apr;13(3):181-6. PubMed, CrossRef
  8. He S, Zhu K, Skeppholm M, Vedin J, Svensson J, Egberg N, Blombäck M, Wallen H. A global assay of haemostasis which uses recombinant tissue factor and tissue-type plasminogen activator to measure the rate of fibrin formation and fibrin degradation in plasma. Thromb Haemost. 2007 Oct;98(4):871-82. PubMed, CrossRef
  9. Goldenberg NA, Hathaway WE, Jacobson L, Manco-Johnson MJ. A new global assay of coagulation and fibrinolysis. Thromb Res. 2005;116(4):345-56. PubMed, CrossRef
  10. Antovic A. The overall hemostasis potential: a laboratory tool for the investigation of global hemostasis. Semin Thromb Hemost. 2010 Oct;36(7):772-9. Review. PubMed, CrossRef
  11. Mackman N, Taubman M. Tissue factor: past, present, and future. Arterioscler Thromb Vasc Biol. 2009 Dec;29(12):1986-8. Review. PubMed, PubMedCentral, CrossRef
  12. Hedner U. General haemostatic agents – fact or fiction? Pathophysiol Haemost Thromb. 2002;32 Suppl 1:33-6. PubMed, CrossRef
  13. Curnow JL, Morel-Kopp MC, Roddie C, Aboud M, Ward CM. Reduced fibrinolysis and increased fibrin generation can be detected in hypercoagulable patients using the overall hemostatic potential assay. J Thromb Haemost. 2007 Mar;5(3):528-34.  PubMed, CrossRef
  14. Chernukha LM, Kashyrova EV,  Lugovskoy EV,  Komisarenko SV,  Kolesnikov IN, Makohonenko EM, Platonova TN, Pirogova LV, Gornickaya OV. Characteristics of hemostatic system state at arteriovenous forms of congenital vascular malformations. Novosti Khirurgii. 2014 Mar-Apr;22 (2): 191-198. (In Russian).
  15. Lugovskoy EV, Kolesnikova IN, Lugovskaya NE, Litvinova LM, Gritsenko PG, Gogolinskaya GK, Lyashko ED, Kostyuchenko EP, Remizovsky GA, Pedchenko VN, Komisarenko SV. Quantification of D-dimer and soluble fibrin in blood plasma at ischemic heart disease and hypertension. Ukr Biokhim Zhurn. 2004 Nov-Dec;76(6):136-41.  Russian. PubMed
  16. Rublenko АМ, Urvant LP, Маkоgоnenkо YМ, Platonova ТN, Chernyshenko ТМ, Kоlesnikova IM,  Fishchenko VО, Lugovskoi EV. Effect of protein C activator on overall haemostasis potential in donor and hip arthroplasty patient plasma. Ukr Biokhim Zhurn. 2011 Sep-Oct;83(5):32-9. Ukrainian. PubMed
  17. Carr ME Jr, Hermans J. Size and density of fibrin fibers from turbidity. Macromolecules. 1978 Jan-Feb;11(1):46-50. PubMed, CrossRef
  18. Suenson E, Petersen LC. Fibrin and plasminogen structures essential to stimulation of plasmin formation by tissue-type plasminogen activator. Biochim Biophys Acta. 1986 Apr 22;870(3):510-9. PubMed, CrossRef
  19. Sakharov DV, Nagelkerke JF, Rijken DC. Rearrangements of the fibrin network and spatial distribution of fibrinolytic components during plasma clot lysis. Study with confocal microscopy. J Biol Chem. 1996 Jan 26;271(4):2133-8. PubMed, CrossRef
  20. Marder VJ, Francis CW. Plasmin degradation of cross-linked fibrin. Ann N Y Acad Sci. 1983 Jun 27;408(1):397-406. PubMed, CrossRef
  21. Mihalyi E. Kinetics and molecular mechanism of the proteolytic fragmentation of fibrinogen. Ann N Y Acad Sci. 1983 Jun 27;408(1):60-70. PubMed, CrossRef
  22. Suenson E, Bjerrum P, Holm A, Lind B, Meldal M, Selmer J, Petersen LC. The role of fragment X polymers in the fibrin enhancement of tissue plasminogen activator-catalyzed plasmin formation. J Biol Chem. 1990 Dec 25;265(36):22228-37. PubMed
  23. Маkоgоnenkо YМ, Kirра СА, Lugovskoi EV, Nasarenko НА, Kudinov СА.  Kinetics of glu- and lys-plasminogen activation by the tissue activator in a fibrin clot. Biokhimiia. 1987 Oct;52(10):1746-52. Russian. PubMed
  24. Hantgan RR, Hermans J. Assembly of fibrin. A light scattering study. J Biol Chem. 1979 Nov 25;254(22):11272-81. PubMed
  25. Makogonenko E, Tsurupa G, Ingham K, Medved L. Interaction of fibrin(ogen) with fibronectin: further characterization and localization of the fibronectin-binding site. Biochemistry. 2002 Jun 25;41(25):7907-13. PubMed, CrossRef
  26. Lenting PJ, Casari C, Christophe OD, Denis CV. von Willebrand factor: the old, the new and the unknown. J Thromb Haemost. 2012 Dec;10(12):2428-37. Review. PubMed, CrossRef

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License.